VICL - Sector: Healthcare---Industry: Biotechnology & Drugs

[ScottishTrader]

Well unfortunately after yesterdays nice jump, the pennant I drew turned into a descending resistance line - quite possibly just due to profit-taking, but considering VICL's previous pattern of spiking and retracing, I didn't want to take that chance.  Sold out at 5.70, lower than I wanted to, but glad I did, just not comfortable with the intraday chart.

Having said that, it'll probably spike again tomorrow 

You never can tell, but my main goal was to get out without a loss above all else, which I achieved

Here's the recent intraday (15min) chart

[traderjbr]

Might be ready to bounce off support here,got a reversal candlestick(Bullish Piercing) on good volume last session.

[Leaira]

It's still technically in a downtrend.  By definition, a downtrend is when the stock is consistently making lower lows and lower highs from day to day.  I'd wait to see if the stock tests $3.50 before making a decision to buy any.

Leaira

[Av8trader]

If it does bounce, would we have a triple bottom here?

[setravis]

Press Release Source: Inovio Biomedical Corporation


Inovio to Raise Approximately $15.8 Million Through Equity Funding
Monday December 19, 6:00 am ET


SAN DIEGO--(BUSINESS WIRE)--Dec. 19, 2005--Inovio Biomedical Corporation (AMEX: INO - News), a late stage developer of therapies for cancer and other applications using electroporation to deliver drugs and nucleic acids, reported today that it has entered into a definitive agreement with a group of institutional investors as well as Merck & Co. Inc. (NYSE: MRK - News) and Vical Inc. (NASDAQ: VICL - News) to sell approximately $15.8 million of the Company's common stock at $2.40 per share, which represents a premium to the closing price on December 15, 2005. In addition, the Company will issue five-year warrants to purchase 35% of the number of shares of common stock to be sold in the offering at an exercise price of approximately $2.93, a 25% premium to the closing price on December 15, 2005. Closing of the transaction is subject to approval of the terms of the offering by the American Stock Exchange.


In addition to the securities being sold for cash in the private placement, the Company will also be issuing shares of common stock and warrants on the same terms as the corresponding securities that are being sold for cash to certain holders of Inovio's outstanding Cumulative Convertible Preferred Stock in exchange for their Preferred Stock pursuant to existing participation rights applicable to Inovio's new equity financings. Gross cash proceeds from this funding include $2,430,000 due from an investor, as part of its funding commitment made, and promissory note delivered, to Inovio in January 2005.

Cash proceeds from the financing will be used for working capital, including for support of clinical trials for the Company's lead product, its Selective Electrochemical Tumor Ablation System, and general corporate purposes.

The common stock, warrants to purchase common stock and the common stock underlying the warrants, have not been registered under the Securities Act of 1933, as amended, or the securities laws of any jurisdiction, and may not be offered or sold in the United States absent registration or exemption from registration requirements. The Company expects to file a registration statement within 30 days after the closing of the transaction with the Securities and Exchange Commission to register the resale of the shares of common stock issued and to be issued upon exercise of the warrants.

This press release does, and shall, not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This press release contains certain forward-looking statements relating to Inovio's development of its electroporation drug and gene delivery technology and its expectation that the financing will be completed as announced. The terms of the announced financing are subject to approval of the American Stock Exchange and the listing on the American Stock Exchange of the shares and warrant shares to be issued. Moreover, actual events or results relating to Inovio's forward-looking statements concerning the development of its electroporation drug and gene delivery technology may differ from Inovio's expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Inovio's technology by existing and potential strategic partners, capital market conditions, and other factors set forth in Inovio's Annual Report on Form 10-K for the year ended December 31, 2004, and its Quarterly Report on Form 10-Q for the three months ended September 30, 2005, and other filings with the Securities and Exchange Commission. There can be no assurance that any product in the Inovio product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products.

Contact:
Inovio Biomedical Corporation
Bernie Hertel, 858-410-3101 (Investor Relations)
or
Atkins + Associates   
Rebecca Wong, 858-527-3495 (Media Relations)

--------------------------------------------------------------------------------
Source: Inovio Biomedical Corporation

[equity]

I see this trash hyped on various message boards.  Is there some kind of paid promotional campaign for this dog?

The fundamentals are horrible.

[traderjbr]

Nice warm welcome from equity to a new board member.VICL got a small mention on Friday and is technically poised for further gains this week as investors are warming to biotech related stocks.

http://money.cnn.com/2006/01/06/news/companies/birdflu/

[AussieTrader]

This will set the stock on fire....

(RTTNews) - Vical Inc. (VICL) announced its lead three-component influenza DNA
vaccine candidate provided 100% protection in mice and ferrets against lethal
challenges with a highly virulent (Vietnam/1203/2004) H5N1 avian influenza
virus.



Additionally, Vical's vaccine candidate using only two of the three components
provided high levels of protection against multiple human flu strains and
against the H5N1 avian flu strain. 



Based on the results, the company is continuing to advance toward human testing
of the pandemic flu DNA vaccine candidate.

[rdemp52572]

It looks like it's time to pick up some VICL. Looking for some follow through today and a positive PR on the HIV results next week.

http://www.americanbulls.com/StockPage.asp?CompanyTicker=VICL&MarketTicker=NASD&TYP=S

"...As always, the projections made in the conference call were based on our best available information at the time. While specific dates and venues for release of the HIV data were not provided, we believe the data are available internally at the NIH, and could be presented at any time.

In the past, the NIH has presented data at the Keystone symposia on HIV. The Keystone web site shows that Dr. Gary Nabel of the Vaccine Research Center is scheduled to present at the Keystone symposia next Tuesday, March 27, but the specific topics to be covered are not disclosed. We will be watching with interest."

So, it looks like all eyes will be watching the newswires & Keystone next week concerning the results...

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_V/threadview?m=tm&bn=19346&tid=25691&mid=25697&tof=2&frt=2

[setravis]

A 'Pandemic' Now Declared, Focus Back on Swine Flu Stocks
On Friday June 12, 2009, 12:00 pm EDT

The H1N1 virus is officially a pandemic, and vaccine stocks are responding.

Swine flu stocks are up again today, with some extending weekly gains to more than 20%. A number of companies released good news to end the week. From small-cap players to multi-billion dollar giants, shares are up big on high volume. Novartis (NYSE: NVS) announced today that it will have a swine flu vaccine ready by this fall. Shares are up by 4% on the news.

On Thursday, the World Health Organization raised its alert level on the virus to "Phase 6," indicating that it has officially become a pandemic.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 2.5%. It is now beating the S&P 500 by 35.5% over the last month.

Generex Biotechnology (NASDAQ: GNBT) is leading the Index today with 10% gains. The company was granted five new patents for its drug delivery systems. The patents were awarded in Canada, Australia, New Zealand, Brazil, and Lebanon. The stock is still in negative territory this week by -3%.

Sinovac Biotech (AMEX: SVA) is adding another 3% to its industry-leading 30% weekly rally. On Monday the company announced that it had begun production of a swine flu vaccine, and noted that it could produce up to 30 million doses per year.

Vical (NASDAQ: VICL) has fallen from earlier highs, and is now trading up fractionally. Thomas Weisel initiated coverage of the company today with an Overweight rating and a $5 price target. The analyst cited Vical's proprietary technology, strategic partnerships, and licensing agreements.

GlaxoSmithKline (NYSE: GSK) and Hemispherx Biopharma (AMEX: HEB) are both ahead by more than 4% today.

Pure Bioscience (NASDAQ: PURE) and AVI Biopharma (NASDAQ: AVII) are industry laggards today, falling by -3% and -6% respectively.

As of this writing the Swine Flu and Bird Flu Stocks Index is a top-three performing tickerspy Index over the last month, gaining 39.5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.
http://www.tickerspy.com/index/Swine-Flu-and-Bird-Flu-Stocks?refer=2028Y3
     

[setravis]

A 'Pandemic' Now Declared, Focus Back on Swine Flu Stocks
On Friday June 12, 2009, 12:00 pm EDT

The H1N1 virus is officially a pandemic, and vaccine stocks are responding.

Swine flu stocks are up again today, with some extending weekly gains to more than 20%. A number of companies released good news to end the week. From small-cap players to multi-billion dollar giants, shares are up big on high volume. Novartis (NYSE: NVS) announced today that it will have a swine flu vaccine ready by this fall. Shares are up by 4% on the news.

On Thursday, the World Health Organization raised its alert level on the virus to "Phase 6," indicating that it has officially become a pandemic.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 2.5%. It is now beating the S&P 500 by 35.5% over the last month.

Generex Biotechnology (NASDAQ: GNBT) is leading the Index today with 10% gains. The company was granted five new patents for its drug delivery systems. The patents were awarded in Canada, Australia, New Zealand, Brazil, and Lebanon. The stock is still in negative territory this week by -3%.

Sinovac Biotech (AMEX: SVA) is adding another 3% to its industry-leading 30% weekly rally. On Monday the company announced that it had begun production of a swine flu vaccine, and noted that it could produce up to 30 million doses per year.

Vical (NASDAQ: VICL) has fallen from earlier highs, and is now trading up fractionally. Thomas Weisel initiated coverage of the company today with an Overweight rating and a $5 price target. The analyst cited Vical's proprietary technology, strategic partnerships, and licensing agreements.

GlaxoSmithKline (NYSE: GSK) and Hemispherx Biopharma (AMEX: HEB) are both ahead by more than 4% today.

Pure Bioscience (NASDAQ: PURE) and AVI Biopharma (NASDAQ: AVII) are industry laggards today, falling by -3% and -6% respectively.

As of this writing the Swine Flu and Bird Flu Stocks Index is a top-three performing tickerspy Index over the last month, gaining 39.5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.
http://www.tickerspy.com/index/Swine-Flu-and-Bird-Flu-Stocks?refer=2028Y3
     

[setravis]

VICL Vical Announces Encouraging H1N1 Pandemic Influenza Vaccine ...  by GlobeNewswire  Apr 27 2011 6:30AM

SAN DIEGO, Apr 27, 2011 (GlobeNewswire via COMTEX) -- Vical Incorporated (VICL) announced today that more than half of the subjects in the Phase 1 trial of the company's Vaxfectin(R)-formulated vaccine for H1N1 pandemic influenza generated neutralizing antibodies of the type expected to provide protection against the disease. The vaccine was well-tolerated. Vical was the first company to manufacture a vaccine against the H1N1 influenza virus and the first to conduct animal testing during the 2009 outbreaks, and these latest results demonstrated the safety and immunogenicity of that same vaccine in humans.

The trial was supported by U.S. government funding from the Defense Threat Reduction Agency and the U.S. Naval Medical Research Center (NMRC), and was conducted in collaboration with NMRC. Vical announced in February that it had extended its relationship with NMRC to develop the company's platform technology for the rapid development and production of vaccines against emerging infectious diseases. With additional funding under the extended relationship, Vical will work with NMRC under this contract to establish systems and procedures for the application of Vical's DNA delivery technology, with the goal of protecting military personnel from the threat of new pathogens in the early stages of outbreaks.

"We clearly demonstrated the speed and safety of our approach during the 2009 H1N1 pandemic influenza outbreaks," said Larry R. Smith, Ph.D., Vical's Vice President of Vaccine Research. "The encouraging results of our Phase 1 clinical testing of our H1N1 vaccine, coupled with the successful Phase 1 clinical testing of our H5N1 avian-origin influenza vaccine, provide further validation for both our vaccine platform and our Vaxfectin(R) adjuvant. Through our collaboration with NMRC, we are working toward establishing an emerging disease vaccine platform to provide rapid protection against novel pathogens, initially for military personnel and eventually for the broader population."

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com .

The Vical Incorporated logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5768

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Risks and uncertainties include whether Vical will receive all, if any, of the U.S. government funding; whether funding will be sufficient to complete the planned preparatory efforts; whether Vical or others will continue development of any emerging disease vaccine candidates; whether the company's Vaxfectin(R) adjuvant will be used in any future vaccine candidates; whether future infectious diseases will emerge, and if so, whether DNA vaccines will be successfully applied against them; whether any other DNA vaccine candidates will be shown to be safe and effective in clinical trials; the timing, nature and cost of clinical trials; whether Vical will further extend its collaboration with the U.S. government; whether the neutralizing antibodies generated in the Phase 1 trial of the H1N1 vaccine will provide protection against the disease; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Vical Incorporated


CONTACT: Alan R. Engbring
(858) 646-1127
Website: 
                              www.vical.com
                           

[setravis]

Vical Announces Encouraging H1N1 Pandemic Influenza Vaccine Phase 1

InPlay...
6:51AM Vical announces encouraging H1N1 pandemic influenza vaccine phase 1 results (VICL) 3.69 : Co announces that more than half of the subjects in the Phase 1 trial of the company's Vaxfectin-formulated vaccine for H1N1 pandemic influenza generated neutralizing antibodies of the type expected to provide protection against the disease. The vaccine was well-tolerated. Vical was the first company to manufacture a vaccine against the H1N1 influenza virus and the first to conduct animal testing during the 2009 outbreaks, and these latest results demonstrated the safety and immunogenicity of that same vaccine in humans.



Technicals
Gap Up
Percentage Gainer

Last Price Quote is:
14.78%above 13-day MA
34.85%above 50-day MA
RS Rating: 97 

[setravis]

cancer, viruses, lots of trials going.
extended its relationship with the U.S. Naval Medical Research Center to develop its platform technology for the rapid development and production of vaccines against emerging infectious diseases.

Day's Range: 3.92 - 4.75
52wk Range: 1.70 - 4.75
Volume: 2,299,982
Avg Vol (3m): 901,929
Market Cap: 339.12M
P/E (ttm): N/A
EPS (ttm): -0.51
Div & Yield: N/A (N/A)


Technicals
Record Price High
Percentage Gainer

Last Price Quote is:
27.71%above 13-day EMA
52.59%above 50-day EMA
RS Rating: 98